The Intel of precision motors for advanced surgical instruments.

Qualcomm for the electromechanical core of specialized medical devices.

• Medical Rotary Handpieces: Design and manufacturing of high-speed, precision rotary surgical instruments and systems for various medical applications.
• Dental Devices: Production of advanced dental handpieces and components, including those used for prophylaxis, endodontics, and other dental procedures.
• Industrial & Aerospace Miniature Electric Motors and Gearboxes: Custom engineering and manufacturing of miniature electric motors, gearboxes, and motion control systems for high-reliability industrial and aerospace applications.

Pro-Dex (PDEX) Major Customers

Pro-Dex (PDEX) primarily sells to other companies, operating on a Business-to-Business (B2B) model. Its core business involves providing design, development, and manufacturing services for medical device manufacturers and other technology companies.

While Pro-Dex's financial filings indicate a significant concentration of revenue from a limited number of customers, the company does not publicly disclose the specific names of these major customers in its SEC filings (such as the 10-K reports), typically citing confidentiality agreements.

For example, in its most recent annual report, Pro-Dex stated:

• Sales to its top five customers accounted for approximately 74% and 79% of total net revenues for the fiscal years ended June 30, 2023 and 2022, respectively.
• During the fiscal year ended June 30, 2023, two customers individually accounted for 20% or more of net revenues, representing approximately 25% and 21% of net revenues, respectively.
• During the fiscal year ended June 30, 2022, three customers individually accounted for 10% or more of net revenues, representing approximately 29%, 22%, and 11% of net revenues, respectively.

Therefore, while Pro-Dex relies heavily on a few large customers, their specific identities (company names and symbols) are not publicly available information from the company's disclosures.

The primary category of companies it serves consists of:

• Medical device manufacturers (OEMs - Original Equipment Manufacturers)
• Other technology companies requiring precision manufacturing and design services

Richard L. Van Kirk, President, Chief Executive Officer, Chief Operating Officer, and Director

Richard L. Van Kirk joined Pro-Dex's Board of Directors and was appointed Chief Executive Officer in January 2015. He initially joined Pro-Dex in January 2006, becoming Vice President of Manufacturing in December 2006 and Chief Operating Officer in April 2013. His career spans over 13 years of management experience in manufacturing. Before Pro-Dex, Mr. Van Kirk served as Manufacturing Manager and Manager of Product Development at Comarco Wireless Technologies, ChargeSource Division. He was also General Manager at Dynacast, a leader in precision die casting. Mr. Van Kirk holds a BA in Business Administration from California State University, Fullerton, and an MBA from Claremont Graduate School.

Alisha Charlton, Chief Financial Officer and Principal Accounting Officer

Alisha Charlton joined Pro-Dex in January 2014 as Senior Director of Finance and was promoted to Chief Financial Officer in January 2015. Prior to her tenure at Pro-Dex, Ms. Charlton held various accounting positions at Comarco, Inc. from October 2000 to January 2014, ultimately becoming Chief Accounting Officer in April 2011. Before Comarco, she held accounting and finance roles with CKE Restaurants, Inc. from February 1995 to October 2000. Ms. Charlton began her career in July 1991 with KPMG Peat Marwick (now KPMG LLP) and is a former certified public accountant. She earned a B.A. in Business Economics from the University of California, Santa Barbara.

Nicholas Swenson, Independent Chairman of the Board

Mr. Nicholas Swenson serves as the Independent Chairman of the Board for Pro-Dex, Inc.

Angel Domingo, Director of Quality Systems and Regulatory Affairs

Ms. Angel Domingo joined Pro-Dex's Board of Directors in December 2021 and has served as the Director of Quality Systems and Regulatory Affairs since 2014, having joined the company in 2005. Her responsibilities include ensuring the company's products and Quality Management Systems meet industry, regulatory, and customer requirements throughout the device lifecycle. She possesses extensive MedTech industry experience across Medical Device, In Vitro Diagnostics, Pharmaceuticals, and Bulk Pharm/Chemicals. Angel holds a BS in Biology/Human Physiology with a Chemistry minor from California State University, Long Beach.

Jorge Cuervo, Director of Project Management

Jorge Cuervo joined Pro-Dex in October 2023 as the Director of the Project Management Office. He brings over 25 years of experience in Operations, Project Management, Lean Facilitation, Sales, and Consulting across North America, Europe, and Asia. His most recent role involved leading the PMO and Operations teams at a sector of Bio-Techne.

1. Customer Concentration Risk: A substantial portion of Pro-Dex's revenue is derived from a limited number of customers. In fiscal year 2025, the largest customer accounted for 75% of the company's revenue, while the top three customers collectively comprised 94% of sales. The loss of a key customer or a significant reduction in orders from them would have a material adverse effect on the company's business, financial condition, and results of operations.
2. Tariffs and Global Trade Uncertainty: Pro-Dex faces significant business risks due to increased tariffs imposed by the United States government on imported goods, which began in the first quarter of 2025, and potential reciprocal actions from other countries. These tariffs are likely to increase the costs of raw materials and components sourced through Pro-Dex's supply chain. The unpredictability of tariff rates and the inability to pass these costs onto customers or find alternative suppliers could adversely affect Pro-Dex's financial condition and operational results.
3. Supply Chain Issues: The company is subject to the risk of various supply chain disruptions. Failure to mitigate these issues can impact operations and business results. Such disruptions can be exacerbated by global economic conditions and trade policies, potentially leading to increased costs and delays in obtaining necessary raw materials and components.

Pro-Dex (PDEX) operates in several markets, with quantifiable addressable market sizes identified for its powered surgical instruments and its role in medical device contract manufacturing, as well as related rotary drive systems.

• Powered Surgical Instruments: The global powered surgical instrument market was valued at approximately USD 2.28 billion in 2025 and is projected to reach USD 2.78 billion by 2030, growing at a CAGR of 4.06%. Another estimate valued the global market at USD 2.60 billion in 2024, projected to reach USD 3.13 billion by 2030. North America held the largest revenue share, accounting for 35.45% of the powered surgical instruments market in 2024.
• Medical Device Contract Manufacturing/OEM: The global medical device contract manufacturing market size was calculated at USD 78.61 billion in 2024 and is projected to reach around USD 220.57 billion by 2034, expanding at a CAGR of 10.86% between 2025 and 2034. North America dominated this global market, holding approximately a 39% share in 2024.
• Rotary Drive Systems (General): The global direct drive rotary motor market is projected to reach USD 8.444 billion in 2025 and maintain a CAGR of 7.6% from 2025 to 2033. Additionally, the global rotary indexer market, which includes applications in medical device manufacturing, is projected to reach USD 3.6 billion by 2030, with an expected market value of USD 2.2 billion in 2024. The healthcare industry represented about 15% of the rotary indexer market in 2023. North America is expected to dominate the rotary indexer market in 2024.

Pro-Dex (PDEX) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:

1. Continued Sales of Next-Generation Orthopedic Handpiece: The company has experienced significant growth from the sales of its next-generation orthopedic handpiece, particularly to its largest customer. This product has been a primary engine of recent growth, with sales contributing meaningfully to both quarterly and full-year results, and this trend is anticipated to continue.
2. Expanded Manufacturing Capacity: Pro-Dex has invested in a new operational building, effectively doubling its manufacturing capacity. This expansion in machining and assembly capabilities is expected to support increased demand and facilitate higher order fulfillment.
3. Robust Order Backlog: As of June 30, 2025, Pro-Dex reported a record order backlog of $50.4 million. This substantial backlog is expected to underpin continued revenue and operating income growth into fiscal year 2026.
4. New Product Development and Commercialization: The company is actively investing in future growth and product development, with plans for additional product sales as development projects currently in final testing phases move into commercialization.
5. Customer Base Diversification: While Pro-Dex currently has a high concentration of revenue from a single large customer, management intends to diversify its customer base. Successful expansion to new customers would reduce dependency and open new avenues for revenue growth.

Share Repurchases

• Pro-Dex repurchased 130,148 shares at an aggregate cost of $3.5 million during the fiscal year ended June 30, 2025.
• During the fiscal year ended June 30, 2024, the company repurchased 184,901 shares for a total of $3.5 million.

Share Issuance

• No significant dollar amount of shares issued has been explicitly disclosed as a capital allocation decision in the provided search results for the last 3-5 years.

Inbound Investments

• No information regarding large inbound investments made in Pro-Dex by third-parties over the last 3-5 years is available in the provided search results.

Outbound Investments

• During fiscal year 2025, Pro-Dex liquidated some equity investments, receiving proceeds of $1.9 million and recording a gain of $595,000.

Capital Expenditures

• In the last 12 months (as of an unspecified date in 2025), capital expenditures were approximately $913,000.
• Pro-Dex purchased an industrial building in Tustin, California, in November 2020 to provide additional capacity for expected future growth.
• The substantial build-out of the Tustin property was completed in fiscal 2022, with verification and validation activities concluding in fiscal 2023. The entire assembly and repairs operations moved to this new facility in the fourth quarter of fiscal 2023, and it is now fully operational.